It's tough to say what exactly the partnership for
It's tough to say what exactly the partnership for formulation entails but it does hint at the more important truth. Once we get a partnership or significant cash of some kind we will be looking at starting more Brilacidin phase 2 and 3 trials than you can count on one hand very quickly.
B ABSSSI - Phase 3
B OM - Phase 3
B UP - Phase 3
B HS - Phase 2
B Acne - Phase 2
B Eczema - Phase 2
That's just for starters. Most of those should be very fast moving trials as well. This doesn't even mention big GI conditions once we get a pill either. Bring home the bacon, Leo! Let's get this party started!
Go IPIX!
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
IntelAgree Recognized for Innovation in CLM IntelAgree, a leading player in contract lifecycle management (CLM) powered by artificial intelligence, has recently been honored as an 'Advanced Solution' in a distinguished analysis by The Hackett Group. This recognition solidifies IntelAgree’s reputation as a top platform in the business sector. Importance of The Hackett...
Continue Reading
Emergency Health Professionals Unite with Teamsters Local 120 Recently, a remarkable development unfolded as a dedicated group of 15 paramedics, EMTs, and emergency health professionals came together to join Teamsters Local 120. This resolute decision signifies their commitment to securing better working conditions and fair compensation. The Journey Toward Unionization...
Continue Reading
MSI Unveils Future-Proof Cloud Solutions At CloudFest 2025, MSI, a leader in high-performance server solutions, introduced its innovative next-generation server platforms, including the ORv3 Servers, DC-MHS Servers, and NVIDIA MGX™ AI Servers. This significant event showcased MSI's commitment to enhancing cloud infrastructure with a focus on scalability, performance,...
Continue Reading
St. Cloud Capital's Growth Capital Investment St. Cloud Capital has proudly announced a significant investment in Integrated Diagnostic Services (IDS). This initiative focuses on expanding their capabilities in mobile radiology and laboratory services. The investment aims to support IDS in acquiring Core Analytics Lab & Radiology, a leading provider in California....
Continue Reading
LeMaitre Vascular Shows Robust Growth in Q3 2024 BURLINGTON, Mass. – LeMaitre Vascular, Inc. (NASDAQ: LMAT), a leading provider of vascular devices and services, has reported exceptional results for the third quarter of 2024. The company’s strong performance demonstrates its commitment to innovation in the medical device sector, especially in the area of vascular...
Continue Reading
